- Conditions
- Epistaxis
- Interventions
- Doxycycline, Placebo
- Drug · Other
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Los Angeles, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–31
of 31
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hereditary Hemorrhagic Telangiectasia, Idiopathic Vascular Ectasia
- Interventions
- Pomalidomide
- Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Hereditary Hemorrhagic Telangiectasia (HHT), Epistaxis
- Interventions
- Topical sirolimus ointment
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Hereditary Hemorrhagic Telangiectasia, Epistaxis, Anemia, Nosebleed, HHT
- Interventions
- Pazopanib, Placebo oral capsule
- Drug
- Lead sponsor
- Cure HHT
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Denver, Colorado • Augusta, Georgia + 8 more
- Conditions
- Telangiectasia, Hereditary Hemorrhagic, Epistaxis
- Interventions
- Sterile saline, Bevacizumab, Estriol, Tranexamic Acid
- Drug
- Lead sponsor
- James Gossage
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Augusta, Georgia • Baltimore, Maryland + 3 more
- Conditions
- Hereditary Hemorrhagic Telangiectasia
- Interventions
- Engasertib, Placebo
- Drug
- Lead sponsor
- Vaderis Therapeutics AG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Indianapolis, Indiana • Rochester, Minnesota + 1 more
- Conditions
- Hereditary Hemorrhagic Telangiectasia, Arteriovenous Malformations, Telangiectasia, Epistaxis, GastroIntestinal Bleeding, Cerebral Arteriovenous Malformations, Vascular Malformation
- Interventions
- Not listed
- Lead sponsor
- Cure HHT
- Other
- Eligibility
- Not listed
- Enrollment
- 10,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2033
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Francisco, California + 13 more